Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 aggregate principal amount of its 4.70% Senior Notes, Series A, due December 1, 2023 (the “Series A Notes”) and (ii) $40,000,000 aggregate principal amount of its 4.93% Senior Notes, Series B, due December 1, 2025 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 205,000,000 aggregate principal amount of its 4.706.28% Senior Notes, Series A, due December 1June 26, 2023 2015 (the “Series A Notes”) and (iib) $40,000,000 145,000,000 aggregate principal amount of its 4.936.72% Senior Notes, Series B, due December 1June 26, 2025 2018 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes being hereinafter collectively referred to as the “Notes”, as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and Exhibit 1 or Exhibit 2, as the Series B Notes shall be substantially in the form set out in Schedule 1(b)case may be. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of $100,000,000 aggregate principal amount of Senior Notes consisting of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.705.09% Series A Senior NotesNotes due March 22, Series A, due December 1, 2023 2029 (the “Series A Notes”) and (iib) $40,000,000 50,000,000 aggregate principal amount of its 4.935.17% Series B Senior NotesNotes due March 22, Series B, due December 1, 2025 2029 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in and the form set out in Schedule 1(a) Series B Notes are hereinafter referred to collectively as the “Notes”. The Series A Notes and the Series B Notes shall be substantially in the form forms set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section A and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. (a) The Company will authorize the issue and sale of (ia) $60,000,000 75,000,000 aggregate principal amount of its 4.704.94% Senior Notes, Series AM, due December 1May 31, 2023 2028 (the “Series A M Notes”) and (iib) $€40,000,000 aggregate principal amount of its 4.934.15% Senior Notes, Series BN, due December 1May 31, 2025 2028 (the “Series B N Notes” and, ”; and together with the Series A M Notes, as amended, restated or otherwise modified from time the “Notes,” such term to time pursuant to Section 17 and including include any such notes Notes issued in substitution therefor pursuant to Section 13, the “Notes”13 of this Agreement). The Series A Notes shall be substantially in the form set out in Schedule Exhibit 1(a) and the Series B Notes shall be substantially in the form set out in Schedule Exhibit 1(b)) as appropriate. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specifiedAgreement. References to a “Sectionseries” are references of Notes shall refer to a Section of this Agreement unless otherwise specifiedthe Series M Notes or the Series N Notes, or both, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 50,000,000 aggregate principal amount of its 4.704.57% Guaranteed Senior Unsecured Notes, Series A, due December 1January 24, 2023 2021 (the “Series A Notes”) and (ii) $40,000,000 50,000,000 aggregate principal amount of its 4.935.20% Guaranteed Senior Unsecured Notes, Series B, due December 1January 24, 2025 2021 (the “Series B Notes,” and, and together with the Series A Notes, as amendedcollectively, restated or otherwise modified from time the “Notes,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”14). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-A and 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 100,000,000 aggregate principal amount of its 4.706.26% Senior Notes, Series A, due December 1August 3, 2023 2014 (the “Series A Notes”) and (iib) $40,000,000 300,000,000 aggregate principal amount of its 4.936.44% Senior Notes, Series B, due December 1August 3, 2025 2017 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as the “Notes, as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.706.50% Senior Guaranteed Notes, Series A, due December 1August 7, 2023 2015 (the “Series A Notes”) and (iib) $40,000,000 50,000,000 aggregate principal amount of its 4.937.10% Senior Guaranteed Notes, Series B, due December 1August 7, 2025 2023 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as the “Notes, as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.702.71% Series A Senior NotesUnsecured Notes due July 30, Series A, due December 1, 2023 2019 (the “Series A Notes”) and (iib) $40,000,000 150,000,000 aggregate principal amount of its 4.933.64% Series B Senior NotesUnsecured Notes due July 30, Series B, due December 1, 2025 2024 (the “Series B Notes” and, together with the Series A Notes, as amendedcollectively, restated or otherwise modified from time the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form respective forms set out in Schedule Exhibit 1(a) and Exhibit 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 57,000,000 aggregate principal amount of its 4.707.81% Series E Senior NotesNotes due April 3, Series A, due December 1, 2023 2016 (the “Series A E Notes”) and (iib) $40,000,000 43,000,000 aggregate principal amount of its 4.938.24% Series F Senior NotesNotes due April 3, Series B, due December 1, 2025 2019 (the “Series B F Notes” and, together with the Series A E Notes, as amendedcollectively, restated or otherwise modified from time the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A E and Series F Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. Section 1.1. The Company will authorize the issue and sale of (i) $60,000,000 175,000,000 aggregate principal amount of its 4.705.43% Senior Notes, Series A, due December 1July 7, 2023 2020 (the “Series A Notes”) and (ii) $40,000,000 125,000,000 aggregate principal amount of its 4.931.00% Senior Discount Notes, Series B, due December 1July 7, 2025 2022 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Note being hereinafter collectively referred to as (the “Notes”), as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 250,000,000 aggregate principal amount of its 4.703.69% Senior Unsecured Notes, Series A, due December 1November 21, 2023 2018 (the “Series A Notes”) and (ii) $40,000,000 250,000,000 aggregate principal amount of its 4.934.32% Senior Unsecured Notes, Series B, due December 1November 21, 2025 2023 (the “Series B Notes” and, together with ”) (the Series A Notes and the Series B Notes are collectively referred to as the “Notes”, as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule Exhibit 1(a) and Exhibit 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. (a) The Company will authorize the issue and sale of (ia) $60,000,000 75,000,000 aggregate principal amount of its 4.703.66% Senior Notes, Series AD, due December 1November 29, 2023 (the “Series A D Notes”) ), and (iib) $40,000,000 €38,246,768.26 aggregate principal amount of its 4.933.06% Senior Notes, Series BE, due December 1November 29, 2025 2023 (the “Series B E Notes” and”, and together with the Series A D Notes, as amended, restated or otherwise modified from time the “Notes,” such term to time pursuant to Section 17 and including include any such notes Notes issued in substitution therefor pursuant to Section 13, the “Notes”13 of this Agreement). The Series A Notes shall be substantially in the form set out in Schedule Exhibit 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 40,000,000 aggregate principal amount of its 4.705.61% Senior Notes, Series A, due December 1September 15, 2023 2034 (the “Series A Notes”) and (iib) $40,000,000 30,000,000 aggregate principal amount of its 4.935.91% Senior Notes, Series B, due December 1, 2025 2053 (the “Series B Notes” and, and together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 aggregate principal amount of its 4.702.48% Senior Notes, Series A, due December 1August 15, 2023 2031 (the “Series A Notes”) and (iib) $40,000,000 aggregate principal amount of its 4.932.63% Senior Notes, Series B, due December 1June 15, 2025 2033 (the “Series B Notes” and”, together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 200,000,000 aggregate principal amount of its 4.70Senior Notes consisting of (a) $100,000,000 aggregate principal amount of its 3.20% Series A Senior Notes, Series A, Notes due December 1June 13, 2023 (the “Series A Notes”) and (iib) $40,000,000 100,000,000 aggregate principal amount of its 4.933.37% Series B Senior Notes, Series B, Notes due December 1June 13, 2025 (the “Series B Notes” and, ”; and together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form forms set out in Schedule Exhibit 1(a) and Exhibit 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section B and, for purposes of this Agreement unless otherwise specifiedAgreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 50,000,000 aggregate principal amount of its 4.705.68% Senior Notes, Series A, due December 17, 2023 2017 (the “Series A Notes”) and (ii) $40,000,000 25,000,000 aggregate principal amount of its 4.935.68% Senior Notes, Series B, due December 17, 2025 2018 (the “Series B Notes,” and, and together with the Series A Notes, as amendedare collectively the “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes of either series issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-A and Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of (i) $60,000,000 100,000,000 aggregate principal amount of its 4.70Senior Notes consisting of (i) $50,000,000 aggregate principal amount of its 5.72% Senior Notes, Series A, due December 1September 30, 2023 2019 (the “Series A Notes”) and (ii) $40,000,000 50,000,000 aggregate principal amount of its 4.935.72% Senior Notes, Series B, due December 1March 30, 2025 2020 (the “Series B Notes” and, together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”13 of this Agreement). The Series A Notes shall will be substantially in the form set out in Schedule Exhibits 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b), with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.